Adrian Harrington

Adrian Harrington has extensive experience in value and access leadership within the biopharmaceutical industry, currently serving as the International Value & Access Lead for Friedreich's Ataxia at Biogen since October 2015. Prior roles at Biogen include overseeing global value and access initiatives for Spinal Muscular Atrophy programs, and directing value and access efforts for neuromuscular diseases in Europe and Canada. Before Biogen, Adrian Harrington was a Senior Manager in Health Economics and Outcomes Research at Daiichi Sankyo Europe GmbH, focusing on market access strategies for Lixiana. Earlier experience includes a lead market access writing role at Evidera and account management in strategic communications at AxiCom Cohn & Wolfe. Academic credentials include a BA and MSci in Natural Sciences, a PhD in Biochemistry from the University of Cambridge, and an MSc in Health Economics from City, St George’s, University of London.